Inflammatory and Angiogenic Protein Detection in the Human Vitreous : Cytometric Bead Assay

Abstract EN

Introduction.

To evaluate clinical feasibility and reproducibility of cytometric bead assay (CBA) in nondiluted vitreous samples of patients with age-related macular degeneration (ARMD), diabetic macular edema (DME), and central retinal vein occlusion (CRVO).

Methods.

Twelve patients from a single clinics day qualified for intravitreal injections (ARMD n=6, DME n=3, CRVO n=3) and underwent a combination treatment including a single-site 23 gauge core vitrectomy which yielded a volume of 0.6 mL undiluted vitreous per patient.

Interleukin-6 (IL-6), vascular endothelial growth factor isoform A (VEGF-A), and monocyte chemo-attractant protein-1 (MCP-1) were assessed directly from 0.3 mL at the same day (fresh samples).

To assess the reproducibility 0.3 ml were frozen for 60 days at −80°, on which the CBA was repeated (frozen samples).

Results.

In the fresh samples IL-6 was highest in CRVO (median IL-6 55.8 pg/mL) > DME (50.6) > ARMD (3.1).

Highest VEGF was measured in CRVO (447.4) > DME (3.9) > ARMD (2.0).

MCP-1 was highest in CRVO (595.7) > AMD (530.8) > DME (178).

The CBA reproducibility after frozen storage was examined to be most accurate for MCP1 (P=0.91) > VEGF (P=0.68) > IL-6 (P=0.49).

Conclusions.

CBA is an innovative, fast determining, and reliable technology to analyze proteins in fluids, like the undiluted vitreous, which is important to better understand ocular pathophysiology and pharmacology.

There is no influence of intermittent storage at −80° for the reproducibility of the CBA.